US 12,378,261 B2
One-step, fast, 18F-19F isotopic exchange radiolabeling of difluoro-dioxaborinins and use of such compounds in treatment
Richard Ting, New York, NY (US); Omer Aras, New York, NY (US); Feifei An, New York, NY (US); and Nandi Chen, New York, NY (US)
Assigned to Cornell University, Ithaca, NY (US); and Memorial Sloan Kettering Cancer Center, New York, NY (US)
Appl. No. 17/057,284
Filed by CORNELL UNIVERSITY, Ithaca, NY (US); and MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
PCT Filed May 23, 2019, PCT No. PCT/US2019/033860
§ 371(c)(1), (2) Date Nov. 20, 2020,
PCT Pub. No. WO2019/226962, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/675,519, filed on May 23, 2018.
Claims priority of application No. PCT/US2019/027864 (WO), filed on Apr. 17, 2019.
Prior Publication US 2021/0188880 A1, Jun. 24, 2021
Int. Cl. A61K 51/00 (2006.01); A61K 9/00 (2006.01); A61M 36/14 (2006.01); C07F 5/02 (2006.01)
CPC C07F 5/025 (2013.01) [A61K 9/0019 (2013.01); C07B 2200/05 (2013.01)] 18 Claims
 
1. A compound according to Formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt and/or solvate thereof, wherein
X1 and X2 are each independently 18F or 19F; and
R1 and R3, R2 and R3, or R1, R2, and R3 join to form a substituted or unsubstituted polycyclic ring;
wherein the compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof is tetracycline-BF2, glycylcycline-BF2, emodin-BF2, doxorubicin-BF2, or daunorubicin-BF2.